Cetuximab (anti-EGFR)

CAS No. 205923-56-4

Cetuximab (anti-EGFR)( C225 )

Catalog No. M21142 CAS No. 205923-56-4

Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 260 In Stock
5MG 434 In Stock
10MG 627 In Stock
25MG 981 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cetuximab (anti-EGFR)
  • Note
    Research use only, not for human use.
  • Brief Description
    Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
  • Description
    Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    C225
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    cancer
  • Indication
    Colorectal Cancer

Chemical Information

  • CAS Number
    205923-56-4
  • Formula Weight
    2756.23
  • Molecular Formula
    C107H179N35O36S7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
  • Erlotinib

    A potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.

  • CHF5074

    CHF5074, a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).

  • ZD-4190

    ZD-4190 is a inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling used for the treatment of cancer.